FibroGen, Inc.
FibroGen, Inc., a leading biotechnology company headquartered in the United States, focuses on developing innovative therapies for serious diseases. Founded in 1993, FibroGen has made significant strides in the fields of anaemia, fibrosis, and other critical health conditions, establishing itself as a key player in the biopharmaceutical industry. The company is renowned for its core product, Roxadustat, a novel treatment for anaemia associated with chronic kidney disease, which has garnered attention for its unique mechanism of action. With a strong presence in both the US and international markets, FibroGen continues to expand its portfolio, aiming to address unmet medical needs and improve patient outcomes. The company’s commitment to research and development has positioned it as a notable innovator in the biotechnology landscape.
DitchCarbon Score
How does FibroGen, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
FibroGen, Inc.'s score of 20 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
FibroGen, Inc.'s reported carbon emissions
FibroGen, Inc., headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year, nor does it specify any reduction targets or initiatives. Without specific emissions figures or commitments, it is challenging to assess their climate impact or sustainability efforts. The absence of documented reduction targets suggests that FibroGen may still be in the early stages of formalising its climate strategy. As the industry increasingly prioritises sustainability, it will be important for FibroGen to establish clear climate commitments and measurable goals to align with global efforts in reducing greenhouse gas emissions.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
FibroGen, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
